China, Currency Effects Hit Novartis’s Emerging Market Sales
This article was originally published in PharmAsia News
Emerging markets presented a mixed bag for Novartis last year, with growth in China continuing to slow in the fourth quarter but increasing in smaller more dynamic countries such as Turkey. Sandoz remained strong in Asia but eye care unit Alcon is set for major changes.
Register for our free email digests: